Outsourcing-Pharma.com presents its weekly round-up of the latest changes, faces and places in the pharma services sector, including news from Wolters, Advanced Clinical and BIA.
Charles River Laboratories' deal with AstraZeneca may only formalise an existing relationship but a second Big Pharma accord is good news for the CRO say analysts.
Icon has boosted its Phase I translational medicine services in Manchester, UK, in preparation for what it believes will be a boom in the drug development area.
Access to patient populations is a bigger deciding factor than low cost when selecting a Phase I service provider, according to ISR’s new quality benchmarking report.
Parexel may be willing to act as a matchmaker for the small and midsized developers that work with its new BioPharm unit according to COO Mark Goldberg.
Sigma Aldrich’s fine chemicals manufacturing section SAFC ensured a modest growth for the company although its “weak” research business in the US and the EU has stunted any drastic figures, according to analysts.
Outsourcing-Pharma.com presents its weekly low down of the movers and shakers in the world of pharmaceuticals, including news from Parexel, Ricerca, and CSC.
The billion dollar Korea Drug Development Fund (KDDF) has called on US CRO Parexel to help local developers commercialise pharmaceuticals on the global market.
A quarter of procedures carried out during clinical trials may be pointless according to a new study, which suggests that this unnecessary work costs around $5bn (€3.96bn) a year.
Regulation of clinical trials in emerging markets is now too strict and is prompting sponsors and CROs to adopt “one-size-fits-all” designs, according to a new study.
US CRO Pharmaceutical Product Development (PPD) predicts that new CEO Dave Simmons' ‘pharmaceutical industry experience’ gained at Pfizer will be an asset in guiding partnerships.
inVentiv CEO says PharmaNet and i3 integration ‘essentially complete’ and that – while demand from individual customers can fluctuate - the combination of the two businesses is creating new opportunities.
INC Research says the closure of former Kendle office in Connecticut will better balance resources and that – where possible – staff will be reassigned.
